Lung Cancer
Lung Cancer Content
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORY
Sign me up!We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Dr Helena Yu is an associate attending and the research director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY, USA. read more
In addition to her role as a practising medical oncologist, Dr Yu is a clinical and translational researcher with a focus on improving the survival of patients with EGFR-mutant lung cancers. She oversees the research programme for EGFR-mutant lung cancers at MSK, which includes developing effective new therapies for lung cancer, identifying biomarkers for targeted treatments, lineage plasticity and adaptive mutagenesis as pathways of resistance to targeted therapy, and establishing risk-adaptive treatment strategies that tailor treatment to patients based on risk. Dr Yu has established several mechanisms of resistance to first- and third-generation EGFR tyrosine kinase inhibitors and reported on the prognostic significance of concurrent alterations in EGFR-mutant lung cancer seen on next-generation sequencing.Â
Dr Yu has been the principal investigator of 30 clinical trials, including 10 investigator-initiated trials, focused on EGFR-mutant lung cancer.
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
European Institute of Oncology, Milan, Italy
Dr Antonio Passaro is a medical oncologist and currently holds the position of senior staff physician at the Division of Thoracic Oncology, European Institute of Oncology in Milan, Italy. read more
Dr Passaro is a global authority and leader in lung cancer research and clinical practice. His main areas of research and clinical interest are predictive biomarkers, in particular EGFR and related targeted and immunotherapy agents, from discovery to validation in the clinical setting. He is also highly involved in the use of targeted agents in non-metastatic settings, either alone, or in a multimodality approach, for early or locally-advanced disease.Â
Dr Passaro is involved in a portfolio of many clinical trials, both industry-funded and academic, investigating a range of novel lung cancer therapies. He has published more than 120 articles in peer-reviewed journals. He also serves as a member of several national and international scientific committees. Notably, he has authored guidelines for ESMO (European Medical Society for Medical Oncology) and AIOM (Italian Association of Medical Oncology), guiding the management and treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
University of California, Los Angeles (UCLA), Los Angeles, CA, USA
Dr Aaron Lisberg is a thoracic medical oncologist at the University of California, Los Angeles (UCLA), USA. read more
Dr Lisberg specializes in novel drug development, antibody–drug conjugates (ADCs), immunotherapy and metabolically-targeted therapies in patients with advanced malignancies, with a focus on lung cancer. He is board-certified in haematology and medical oncology.
Dr Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies and has a wide range of ongoing research projects, including the evaluation of factors predictive of response or toxicity to ADCs and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumour alterations. He is also the clinical principal investigator and sub-investigator of several clinical trials evaluating novel therapeutics in various malignancies, including phase I, II and III assessments.
Dr Aaron Lisberg discloses: Advisory board or panel speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Grants/research support from AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics and WindMIL Therapeutics, Inc.
University of Verona, Verona, Italy
Dr Sara Pilotto is a medical oncologist and associate professor at the University of Verona in Verona, Italy. read more
Dr Pilotto completed her graduate studies and residency in medical oncology at the University of Verona and trained in the Translational Research Unit at the Pangaea Biotech laboratory, Quiron-Dexeus University Hospital in Barcelona, Spain. In 2019, she completed her PhD in Inflammation, Immunity and Cancer at the University of Verona in Italy.
Dr Pilotto leads the clinical and research team dedicated to thoracic malignancies at the University of Verona, as well as the FORCE (Focus on Research and Care) team, an integrated group dedicated to a comprehensive approach to patients with cancer (with a specific focus on nutrition and physical activity).
Dr Pilotto is a member of the Lung Cancer Guidelines Experts Panel of a Italian Association of Medical Oncology (AIOM) and a member of the European Society of Medical Oncology (ESMO) Leadership Program 2019.
Dr Sara Pilotto discloses: Advisory board/panel speaker fees from Amgen, Astrazeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda. Consultancy fees from Boehringer Ingelheim. Speaker’s bureau fees from Amgen, Astrazeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda.